Wegovy vs Saxenda (semaglutide vs liraglutide)

Which is better, semaglutide or liraglutide?

Semaglutide wins on head-to-head evidence (STEP 8), on convenience (weekly versus daily), and on the breadth of its label, which includes cardiovascular risk reduction in obesity without diabetes (SELECT) and an oral form. Liraglutide remains the better choice when price is the deciding factor, since generic liraglutide pens are on the market and no generic semaglutide exists, or when a provider wants a daily drug that can be stopped quickly. Both are lawful prescription products. Routine compounding of semaglutide ended in 2025, while liraglutide injection remains on FDA's drug shortage list as of September 2026, so ask any pharmacy offering compounded liraglutide which FDA rule it relies on. [1] [5] [7] [11] [12] [16]

How do semaglutide and liraglutide compare?

Semaglutide and Liraglutide compared by dimension
Dimension	SemaglutideFavored	Liraglutide
Head-to-head evidence [1]	Lost 15.8% of body weight at 68 weeks with 2.4 mg weekly in STEP 8.	Lost 6.4% of body weight at 68 weeks with 3.0 mg daily in STEP 8.
Note: STEP 8 randomized 338 adults with overweight or obesity and no diabetes. The 9.4 percentage point difference favoring semaglutide is the largest gap between two approved GLP-1 agonists in a direct trial.
Placebo-controlled weight loss [2] [3] [4]	14.9% vs 2.4% for placebo at 68 weeks in STEP 1 (1,961 adults).	8.4 kg vs 2.8 kg for placebo at 56 weeks in SCALE Obesity and Prediabetes (3,731 adults), roughly 8% of body weight; 6.0% vs 2.0% in SCALE Diabetes.
Note: Cross-trial comparisons are less reliable than STEP 8, but they point the same way.
Cardiovascular outcomes [5] [6] [7]	SELECT: hazard ratio 0.80 for major adverse cardiovascular events in 17,604 adults with obesity and cardiovascular disease without diabetes. SUSTAIN-6: hazard ratio 0.74 in type 2 diabetes.	LEADER: hazard ratio 0.87 for major adverse cardiovascular events in 9,340 adults with type 2 diabetes over a median 3.8 years, with lower cardiovascular death (hazard ratio 0.78). No cardiovascular outcomes trial in obesity without diabetes.
FDA labeled indications [8] [9] [10]	Wegovy: chronic weight management (adults and adolescents 12 and older), cardiovascular risk reduction in established cardiovascular disease with obesity or overweight, and noncirrhotic MASH. Ozempic: type 2 diabetes, cardiovascular risk reduction, and chronic kidney disease in type 2 diabetes. Rybelsus: oral, type 2 diabetes.	Saxenda: chronic weight management in adults and adolescents 12 and older. Victoza: type 2 diabetes (adults and children 10 and older) and cardiovascular risk reduction in type 2 diabetes with established cardiovascular disease.
Route and dosing frequency [8] [9]	Subcutaneous injection once weekly; oral tablet once daily available as Rybelsus.	Subcutaneous injection once daily from a prefilled pen; no oral form.
Note: Liraglutide's half life of about 13 hours versus semaglutide's roughly one week explains the difference.
Label dose escalation [8] [9]	Wegovy: 0.25 mg weekly for 4 weeks, then 0.5, 1, 1.7, and 2.4 mg at 4-week steps.	Saxenda: 0.6 mg daily, increased by 0.6 mg each week to 3.0 mg daily. Victoza: 0.6 mg for one week, then 1.2 mg, optional 1.8 mg.
Common side effects [1] [2] [3] [8] [9]	Nausea 44%, diarrhea 32%, vomiting 24%, constipation 24% in STEP 1 (versus 16%, 16%, 6%, and 11% on placebo).	Nausea, diarrhea, constipation, and vomiting, mostly mild to moderate; heart rate rises about 2 to 3 beats per minute; serious adverse events 6.2% vs 5.0% placebo in SCALE.
Note: Both labels carry the thyroid C-cell boxed warning and contraindicate use with a personal or family history of medullary thyroid carcinoma or MEN 2. In STEP 8 the kinds of gastrointestinal events were similar between the two drugs.
Regulatory and compounding status [9] [11] [12] [14] [15] [16]	FDA approved (Ozempic 2017, Rybelsus 2019, Wegovy 2021). Shortage-based compounding ended in spring 2025; no generic.	FDA approved (Victoza 2010, Saxenda 2014). First generic liraglutide approved December 2024, with generics referencing Saxenda following in 2025. FDA listed liraglutide injection as in shortage in its October 2024 and February 2025 GLP-1 updates, and FDA's Drug Shortages database still lists it as of September 2026, with Victoza and Saxenda at limited availability. Brand and generic liraglutide are marketed, and on April 30, 2026 FDA proposed not to include liraglutide on the 503B bulks list; that proposal was not final as of September 2026. Ask any pharmacy offering compounded liraglutide which FDA rule it relies on.
Typical cost [8] [9] [11]	Wegovy list price about 1,349 USD per month; manufacturer cash pricing roughly 349 to 499 USD per month; 0 to 25 USD with commercial coverage and a savings card.	Saxenda list price about 1,349 USD per month, but generic liraglutide pens at the diabetes strength run roughly 200 to 500 USD cash; often 25 to 100 USD with commercial coverage.
Note: Prices at the verification date change often; see the cost pages.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Semaglutide and Liraglutide: grade, status, and cost
Attribute	Semaglutide	Liraglutide
Class	GLP-1 receptor agonist (31 amino acid analog of human GLP-1, acylated for once weekly dosing)	GLP-1 receptor agonist (acylated analog of human GLP-1, 97% sequence homology, once daily dosing)
What it is	FDA approved GLP-1 agonist with about 15% average weight loss in a 68 week RCT and proven cardiovascular benefit.	First daily GLP-1 drug: FDA approved since 2010, about 8% weight loss at 3 mg over 56 weeks, proven heart benefit, now available as a generic.
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: FDA approved	Regulatory: FDA approved
Compounding	FDA approved products (Ozempic 2017, Rybelsus 2019, Wegovy 2021). FDA removed semaglutide from the drug shortage list on February 21, 2025; compounding by 503A pharmacies had to stop by April 22, 2025 and by 503B outsourcing facilities by May 22, 2025, except for a documented patient specific clinical need. FDA has warned about unapproved compounded and counterfeit GLP-1 products and salt forms (semaglutide sodium, semaglutide acetate) that are not the approved active ingredient. On April 30, 2026 FDA proposed not to include semaglutide on the 503B bulks list; that proposal was not final as of September 2026. Adding a vitamin such as B12 or niacinamide does not by itself make a compounded GLP-1 different from the approved drug. Under FDA's April 1, 2026 policy update, such a combination may be treated as essentially a copy when the strengths are within 10% of approved products and the route is the same, unless a prescriber documents a real difference for the individual patient. A September 2026 FDA warning letter applied this to semaglutide and tirzepatide vitamin combinations, said high production volume suggested the claimed differences were a pretext, and questioned significant-difference statements picked from preset menus on prescribing platforms.	FDA approved products (Victoza January 2010, Saxenda December 2014). FDA approved the first generic liraglutide referencing Victoza in December 2024, and generic products referencing Saxenda followed in 2025, so branded, generic, and authorized generic pens are all on the market. FDA listed liraglutide injection as in shortage in its October 2024 and February 2025 GLP-1 updates, and FDA's Drug Shortages database still lists it as of September 27, 2026 (first posted July 18, 2023; updated September 22, 2026), with Victoza and Saxenda presentations at limited availability and unbranded presentations available. FDA states that a compounded drug may not be identical or nearly identical to an FDA-approved drug unless the approved drug is on FDA's drug shortage list. On April 30, 2026 FDA proposed not to include liraglutide on the 503B bulks list; that proposal was not final as of September 2026. Ask any pharmacy offering compounded liraglutide which FDA rule it relies on.
WADA	WADA: Not WADA prohibited	WADA: Not WADA prohibited
Routes	Subcutaneous injection once weekly (Ozempic, Wegovy), Oral tablet once daily (Wegovy tablets, Ozempic tablets, Rybelsus)	Subcutaneous injection once daily (prefilled pen)
Typical cost	Manufacturer list price is 1,349.02 USD per month for Wegovy and 1,027.51 USD for Ozempic (checked 2026-09-22), falling to 675 USD for both on January 1, 2027. Manufacturer self-pay prices run 149 to 499 USD per month by product and dose, with the Wegovy pen at 349 USD. With commercial insurance the manufacturer savings offer can bring a covered prescription to 25 USD per month, and eligible Medicare Part D enrollees pay 50 USD per month for Wegovy under the Medicare GLP-1 Bridge (July 2026 to December 2027). A 2024 study found compounded semaglutide at a median 231 USD for the first month during the shortage; compounding is now limited to patient specific needs.	Manufacturer list price is 1,349.02 USD per month for Saxenda and 543.51 to 815.27 USD per month for Victoza depending on the daily dose (checked 2026-09-22). Generic liraglutide pens cost from about 112 USD per month for the diabetes strength and about 372 USD for the 3 mg weight management generic with a discount card, against average retail prices of about 616 to 924 USD. With commercial insurance the Saxenda savings card can bring a covered prescription to 25 USD. Medicare Part D covers liraglutide for type 2 diabetes but generally not for weight loss alone, and the Medicare GLP-1 Bridge does not include it.
Last verified	Sep 27, 2026	Sep 27, 2026

Has semaglutide been tested directly against liraglutide?

Direct comparisons of Semaglutide and Liraglutide
Study	Design and population	Outcome	Grade
Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes (STEP 8)2022 PMID 35015037	Phase 3b randomized, open-label, placebo-controlled trial, 68 weeksn = 338 Adults with BMI 30 or higher, or 27 or higher with at least one weight-related comorbidity, without diabetes	Mean weight change 15.8% with semaglutide 2.4 mg weekly vs 6.4% with liraglutide 3.0 mg daily (difference 9.4 percentage points)	Evidence: Human RCT evidence

What do semaglutide and liraglutide cost?

Typical cost of Semaglutide and Liraglutide
Dimension	Semaglutide	Liraglutide
Typical cost	$149 to $1,349 per month	$112 to $1,349 per month
Price detail	Semaglutide price by channel	Liraglutide price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Wegovy vs Saxenda: which causes more weight loss?

Semaglutide, by a wide margin. In STEP 8, the direct comparison in 338 adults without diabetes, semaglutide 2.4 mg weekly produced 15.8% weight loss at 68 weeks versus 6.4% with liraglutide 3.0 mg daily. The separate placebo-controlled trials agree: about 15% in STEP 1 for semaglutide versus about 8% in SCALE for liraglutide. [1] [2] [3]

Is Saxenda or generic liraglutide cheaper than Wegovy?

Usually, because liraglutide is generic and semaglutide is not. Generic liraglutide pens at the diabetes strength have brought cash prices to roughly 200 to 500 USD per month, versus about 1,349 USD list for Wegovy or roughly 349 to 499 USD through the manufacturer cash program. With commercial coverage and savings cards both can be inexpensive, so check coverage for your indication first. [8] [9] [11]

Do Ozempic and Victoza both protect the heart?

Both have positive cardiovascular outcomes trials, but in different populations. Liraglutide's LEADER trial showed a 13% relative reduction in major adverse cardiovascular events in people with type 2 diabetes. Semaglutide has that too (SUSTAIN-6) plus SELECT, which showed a 20% relative reduction in people with obesity and cardiovascular disease but no diabetes, and Wegovy carries an indication for that use. Saxenda does not. [5] [6] [7] [8]

Are the side effects different?

Not in kind. Both cause nausea, diarrhea, vomiting, and constipation that peak during dose escalation, and both labels carry the thyroid C-cell boxed warning. Liraglutide's daily dosing means side effects can be stopped faster, while semaglutide's weekly half life means an adverse effect persists for days after a dose. [2] [3] [8] [9]

Can I switch from Saxenda to Wegovy?

Switching is common in practice, but neither label includes a switching schedule and STEP 8 did not study it. The Wegovy label starts at 0.25 mg weekly regardless of prior GLP-1 exposure. Discuss timing with the prescriber rather than following an online protocol. [1] [8]

Can either be compounded?

Semaglutide, not routinely: FDA ended the shortage-based allowance for compounded semaglutide in spring 2025. Liraglutide is different: FDA listed liraglutide injection as in shortage in its October 2024 and February 2025 GLP-1 updates, and FDA's Drug Shortages database still lists it as of September 2026, with Victoza and Saxenda at limited availability. FDA states that a compounded drug may not be identical or nearly identical to an FDA-approved drug unless the approved drug is on FDA's drug shortage list. Brand and generic liraglutide are also marketed, and on April 30, 2026 FDA proposed not to include liraglutide on the 503B bulks list. Ask any pharmacy offering compounded liraglutide which FDA rule it relies on. [11] [12] [14] [15] [16]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 27). Semaglutide vs liraglutide: evidence, cost, and legality. https://peptideagent.ai/compare/semaglutide-vs-liraglutide
HTML link: <a href="https://peptideagent.ai/compare/semaglutide-vs-liraglutide">Semaglutide vs liraglutide: evidence, cost, and legality</a>, PeptideAgent, updated September 27, 2026.

Wegovy vs Saxenda and Ozempic vs Victoza (semaglutide vs liraglutide)

The short answer